Uromodulin protein as a guide for kidney care in multiple myeloma
Part of Cancer, Kidney & urinary clinical trials.
This study looks at a protein called uromodulin in the blood and urine to see if it can help doctors manage kidney problems in people with multiple myeloma. If you have newly diagnosed myeloma, and your kidney issues are caused by the myeloma itself, this trial might help improve how your treatment is monitored.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You have been newly diagnosed with multiple myeloma (a cancer of plasma cells in the bone marrow).
- You may or may not have kidney problems related to the myeloma.
- Your kidney damage must not be from other causes, such as diabetes, high blood pressure, or lupus.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a simple blood test can help track multiple myeloma. It will measure a protein called soluble BCMA that may indicate how active the disease is, potentially helping doctors monitor patients without frequent bone marrow tests.
This study is testing whether a blood test that measures a protein called BCMA can help doctors know if your multiple myeloma is getting worse. You may be able to join if your myeloma has come back or not responded to at least two prior treatments, and you have not taken the drug Ruxolitinib before.
This trial tests a combination of two drugs, CM336 and isatuximab, for people newly diagnosed with multiple myeloma who also have kidney problems caused by the disease. The goal is to see if this combination can help control the myeloma while also improving kidney function.
This trial tests a new combination of drugs (daratumumab, bortezomib, and dexamethasone) against the usual combination (cyclophosphamide, bortezomib, and dexamethasone) in people with newly diagnosed multiple myeloma who also have kidney failure. The goal is to see if the new combination works better and helps protect kidney function.
This trial tests a new treatment called UTAA17 that targets a protein on myeloma cells. It may be an option for people whose multiple myeloma has not responded to several prior treatments.
This study looks at simple blood test results from people newly diagnosed with multiple myeloma to see if those results can help predict how the disease may progress. It aims to find patterns in the blood that might guide future treatment decisions without any extra procedures or drugs.
Hear when a new Multiple Myloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.